Eagle Health Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eagle Health Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.7M	Buy	624,676 +118,867	+24%	+$6.51M	5.92%	5
2026 Q1	$28.6M	Buy	505,809 +138,997	+38%	+$8.1M	5%	6
2025 Q4	$21.8M	Hold	366,812	–	–	4.79%	8
2025 Q3	$19.9M	Hold	366,812	–	–	5.22%	8
2025 Q2	$20.2M	Sell	366,812 -15,800	-4%	-$930K	4.98%	9
2025 Q1	$27M	Sell	382,612 -36,600	-9%	-$2.46M	7.02%	6
2024 Q4	$27.6M	Hold	419,212	–	–	6.76%	6
2024 Q3	$29.5M	Buy	419,212 +187,412	+81%	+$15.7M	5.58%	10
2024 Q2	$19.1M	Buy	+231,800	New	+$19.3M	3.35%	13

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Eagle Health Investments's BMRN Position: Q2 2026 in Review

Eagle Health Investments increased its BioMarin Pharmaceuticals (BMRN) stake by 24% in Q2 2026, buying an estimated $6.51M and bringing the position to 624,676 shares worth $35.7M. The position accounts for 5.92% of the portfolio, ranked #5.

Eagle Health Investments first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Eagle Health Investments held 624,676 shares of BioMarin Pharmaceuticals worth $35.7M as of Q2 2026.
Eagle Health Investments bought 118,867 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $6.51M.
BioMarin Pharmaceuticals made up 5.92% of Eagle Health Investments's portfolio in Q2 2026, its #5 holding.
Eagle Health Investments first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.